Bivalirudin in patients with the acute coronary syndrome: the real clinical practice based on evidence medicine

DOI: https://doi.org/10.25512/DIR.2014.08.1.08

For quoting:
Shugushev Z.K., Maximkin D.A., Petrov A.S., Kolzhecova Ju.S. "Bivalirudin in patients with the acute coronary syndrome: the real clinical practice based on evidence medicine". Journal Diagnostic & interventional radiology. 2014; 8(1); 55-61.

authors:

Shugushev Z.K.

Maximkin D.A.

Petrov A.S.

Kolzhecova Ju.S.

keywords:

bivalirudin

acute coronary syndrome

monofram

unfractionated heparin

bleeding

MACEs

Abstract:

The presented research on studying the efficiency and safety of various anticoagulants used in patients with acute coronary syndrome during percutaneous coronary interventions (PCI). High efficiency of a Bivalirudin is shown, in comparison with Unfractionated Heparin and Monofram on the amount of bleeding arising in the postoperative period and main adverse coronary events (MACE).

References

1. Bolezni serdca: Rukovodstvo dlja vrachej [Heart diseases: Manual for doctors]. (Pod red. R.G. Oganova, I.G. Fominoj) M. Litera. 2006; 1328 [In Russ].

2. Rukovodstvo po kardiologii. Pod red. V.N. Kovalenko [Manual on cardiology edited by V.N.Kovalenko]. K. MORION. 2008; 1424 [In Russ] .

3. Volozh O.I., Deev A.D., Kal'juste T.I. Prognosticheskoe znachenie nekotoryh faktorov dlja smertnosti trudosposobnogo vozrasta (prospektivnoe jepidemiologicheskoe issledovanie) [Prognostic value of some factors for estimation of mortality of able-bodied age (prospective epidemiologic study)]. Kardiologija. 1997; 9: 43-48 [In Russ].

4. Oganov R.G. Pervichnaja profilaktika ishemicheskoj bolezni serdca [Primary prophylaxis of ischemic heart disease]. M. Medicina. 1990; 160 [In Russ].

5. Paolo G. Camici, Sanjay Kumak Prosad, Omela E. Rimoldi. Stunning, Hybernating and Assesment of Myocardial Viability. Circulation, 2008; 117: 103-114.

6. Aasa M., Dellborg M., Herlitz J. et al. Risk reduction for cardiac events after primary coronary intervention compared with thrombolysis for acute ST elevation myocardial infarction (five year results of the Swedish early decision reperfusion strategy [SWEDES] trial). Am. J. Cardiol. 2010; 106 (12): 1685-1691.

7. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 - Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2011; 123: e426-e579.

8. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002; 359: 294-302.

9. Doyle B.J., Rihal C.S., Gastineau D.A., Holmes D.R. Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am. Coll. Cardiol. 2009; 53: 2019-2027.

10. Kastrati A., Neumann F.J., Schulz S., Massberg S. et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N. Engl. J.Med. 2011; 365(21): 1980-1989.

11. Kessler D.P., Kroch E., Hlatky M.A. et al. The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction. Am. Heart. J. 2011; 162: 494-500.

12. Linkins L.A., Warkentin T.E. Heparin-induced thrombocytopenia: real-world issues. Semin Thromb Hemost 2011; 37(6): 653-663.

13. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur. Hear. J. 2008; 29: 2909-2945.

14. Budaj A., Eikelboom J.W., Mehta S.R. et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur. Heart J. 2009; 30:655-661.

15. Mehran R., Pocock S.J., Stone G.W. et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-eleva- tion acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009; 30:1457-1466.

16. Bittle J.A., Chaitman B.R., Feit F. et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am. Heart J. 2001; 142(6):952-959.

17. Montalescot G., Baldit-Solier C., Chibedit D. et al. for the ARMADA investigators. ARMADA study: a randomized comparison of enoxaparin, dalteparin and unfractional heparin on markers off cell activation in patients with unstable angina. Am. J. Cardiol. 2003; 91: 925-930.

18. Montalescot G., Collet G.P., Lison L. et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J. Am. Coll. Cardiol. 2000; 36:100-114.

19. Kokov L.S., Lopotovsky P.Yu., Parkhomenko M.V., Larin A.G., Korobenin A.Yu. Experience with the Use of Angiox (Bivalirudin) in Acute Coronary Syndrome (ACS) Patients with Complications Caused by Percutaneous Coronary Intervention (PCI). International Journal of InterventionalCardioangiology, 2013; 34: 39-42.

20. Manoukian S.V., Feit F., Mehran R. et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J. Am. Coll. Cardiol. 2007; 49(12): 1362-1368.

21. Stone G.W., Witzenbichler B., Guagliumi G. et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicenter, randomized controlled trial. Lancet 2011; 377(9784): 2193-2204.

22. Steg G., Stefan K. James, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33:2569-2619.